Potentiation of neuromuscular transmission by a small molecule calcium channel gating modifier improves motor function in a severe spinal muscular atrophy mouse model

• Published in: Human molecular genetics Vol. 32; no. 11; pp. 1901 - 1911
• Main Authors: Ojala, Kristine S, Kaufhold, Cassandra J, Davey, Mykenzie R, Yang, Donggyun, Liang, Mary, Wipf, Peter, Badawi, Yomna, Meriney, Stephen D
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 18.05.2023
• Subjects: Activities of Daily Living; Animals; Disease Models, Animal; Humans; Mice; Motor Neurons - physiology; Muscle, Skeletal; Muscular Atrophy, Spinal - drug therapy; Muscular Atrophy, Spinal - genetics; Survival of Motor Neuron 1 Protein; Synaptic Transmission
• ISSN: 0964-6906; 1460-2083
• DOI: 10.1093/hmg/ddad019

Abstract Spinal muscular atrophy (SMA) is a monogenic disease that clinically manifests as severe muscle weakness owing to neurotransmission defects and motoneuron degeneration. Individuals affected by SMA experience neuromuscular weakness that impacts functional activities of daily living. We have used a mouse model of severe SMA (SMNΔ7) to test whether a calcium channel gating modifier (GV-58), alone or in combination with a potassium channel antagonist (3,4-diaminopyridine; 3,4-DAP), can improve neuromuscular function in this mouse model. Bath application of GV-58 alone or in combination with 3,4-DAP significantly restored neuromuscular transmission to control levels in both a mildly vulnerable forearm muscle and a strongly vulnerable trunk muscle in SMNΔ7 mice at postnatal days 10–12. Similarly, acute subcutaneous administration of GV-58 to postnatal day 10 SMNΔ7 mice, alone or in combination with 3,4-DAP, significantly increased a behavioral measure of muscle strength. These data suggest that GV-58 may be a promising treatment candidate that could address deficits in neuromuscular function and strength and that the addition of 3,4-DAP to GV-58 treatment could aid in restoring function in SMA.